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Abstract
Background: Recruiting patients to large randomised controlled trials (RCTs) in the primary care
setting can be challenging. Research teams need to identify and utilise strategies that both maximise
the efficiency of recruitment and minimise the burden on general practitioners.
Purpose: To describe our methods for identifying, approaching and recruiting female patients aged
50–69 years to a long-term double-blind RCT of hormone therapy (HT) – the Women's
International Study of long Duration Oestrogen after Menopause (WISDOM). The effectiveness of
conducting group seminars with patients prior to one-to-one screening is discussed.
Methods: Female patients aged between 50 and 69 years were sent letters from participating
general practitioners in Adelaide inviting them to participate in WISDOM and attend an initial
seminar providing information about HT and the trial prior to a screening interview with a trial
nurse. Recruitment rates for those who did or did not attend group seminars were compared.
Results: Women who attended a group seminar conducted by the research team were twice as
likely to attend an initial screening visit and enrol to participate in WISDOM than women who did
not attend a seminar (p < 0.001). In addition, it was estimated that the time required to randomise
a woman in the trial, and the number and duration of telephone calls to screen out uninterested
women, was reduced for the seminar group.
Conclusion: Conducting group seminars with potential participants may be a useful strategy for
maximising recruitment from general practice, by increasing patient information and reducing a
research team's workload.
Trial registration: Current Controlled Trials ISRCTN63718836
Background
Recruiting patients to large, population based randomised
controlled trials (RCTs) can be challenging. Firstly, identi-
fication and screening of eligible patients in the chosen
population is required, and this can be a lengthy process
if the study in question has stringent selection criteria. Sec-
ondly, as with all research studies, time needs to be spent
with each patient to ensure that they have a good under-
standing of the study's background, aims and procedures
to enable them to make an informed choice about
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whether or not to participate. This process can be more
involved when the study demands are substantial or the
study requires a long-term commitment from its partici-
pants. In addition, if the study in question is a double-
blind, placebo-controlled RCT, the specific principles
unique to this type of study design need to be understood
and accepted by participants. These principles include [1]
clinical equipoise concerning the research question,
reflecting collective professional uncertainty over a treat-
ment's effectiveness, [2] randomisation to treatment or
placebo and the inability to choose treatment and [3] the
need for blinding to treatment by the patient, general
practitioner and investigators.
Recruiting patients to RCTs in the primary care setting can
be especially challenging. In this setting, research staff
often rely on general practitioners (GPs) and practice
nurses to identify and recruit eligible patients, and moni-
tor patient health outcomes. However, the extent to which
GPs and practice staff can identify and recruit patients for
research is often limited due to time constraints and work-
loads. Thus, the research team often need to identify and
utilise alternative strategies that both maximise the effi-
ciency of recruitment and minimise the burden on GPs.
The purpose of this article is to describe our research
team's methods of identifying, approaching and recruit-
ing female patients aged 50–69 years for participation in
a long-term double-blind RCT of hormone therapy (HT)
– the Women's International Study of long Duration Oes-
trogen after Menopause (WISDOM) [1]. This was to have
been the world's largest and longest randomised placebo
controlled trial. In particular, the effectiveness of conduct-
ing seminars with patients in addition to one-to-one
screening with a research nurse at the pre-recruitment
stage is described.
WISDOM was an international trial conducted in the UK,
Australia and New Zealand that assessed the long-term
benefits and harms of HT use. WISDOM proposed to ran-
domise 22,300 healthy postmenopausal women aged 50
to 69 years to 10 years treatment with oestrogen therapy,
combined oestrogen plus progestogen therapy or placebo,
and follow-up participants for an additional 5 years after
treatment [1]. Four thousand of these participants were to
be recruited in Australia. In October 2002, WISDOM was
stopped following the early results from a similar long-
term RCT of combined HT based in the USA – the
Women's Health Initiative (WHI) [2,3]. The WHI investi-
gators stopped the main arm of their trial – the combined
oestrogen and progestogen therapy arm – when an
increase in breast cancer rates (8 per 10,000 women years)
seen at 5 years of HT use reached statistical significance,
and an increased risk of stroke, thromboembolism, and
heart disease was observed in participants [2]. At the time
of WISDOM's closure, 5692 women had been ran-
domised, and our Adelaide recruitment centre had
screened a total of 840 women for the Australian arm.
Methods
The original protocol for WISDOM recruitment in the UK
involved a medical case note search of all women aged
50–69 in participating general practices [1]. The GP and
trial nurse screened out those with obvious exclusion cri-
teria and the remaining large majority were then informed
about the trial by a postal letter, and then individually
contacted by a nurse to discuss the trial and invited to a
one-to-one information and screening interview for eligi-
bility before obtaining informed consent to proceed to a
pre-trial 'run-in' phase. Despite the recruitment of 384
general practices and a large recruitment team, recruit-
ment was slow and fell behind target in the UK. Australia
was next to commence recruitment and here it was
decided to approach all women aged 50–69 years in each
general practice by inviting them to group seminars about
WISDOM, held in community venues near their practice.
Ethical approval for WISDOM was given by the University
of Adelaide Human Research Ethics Committee and the
Royal Australian College of General Practitioners'
National Research and Evaluation Ethics Committee.
Invitation letter and written information
From May 2001 to July 2002, all female patients aged
between 50 and 69 years were sent letters from participat-
ing GPs in Adelaide inviting them to participate in WIS-
DOM and attend an initial seminar conducted by the
research team. A reply slip, reply paid envelope
(addressed to the research team) and WISDOM informa-
tion sheet were enclosed with the invitation letter. The
information sheet included detailed information about
the trial's background, purpose and procedures, a list of
broad inclusion and exclusion criteria, and a general
explanation of RCT study design (including explanations
of randomisation, use of placebos and blinding). The
reply slip requested that women tick one of four responses
as follows: [1] I am interested in participating in WISDOM
and will attend the information evening, [2] I am inter-
ested in participating in WISDOM but unable to attend
the seminar and/or would prefer a trial nurse to contact
me by telephone, [3] I do not think I am eligible to partic-
ipate in WISDOM based on the information provided in
the enclosed information sheet, or [4] I am not interested
in participating in WISDOM and want no further contact
with the research team.
Seminar
The lay seminars were conducted by the research team
within 2 weeks of the initial invitation mail-out and were
usually conducted in local community centre halls within
close proximity of the woman's general practice. The sem-Trials 2008, 9:5 http://www.trialsjournal.com/content/9/1/5
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inar presentation, conducted by one or more of the local
investigators, followed a standard Microsoft Powerpoint
format and covered the following topics:
Part 1: Discussion of the currently known risks and bene-
fits of HT
(1) The importance of evidence based medicine and the
sources of information that provide health care profes-
sionals with knowledge of evidence based practice and the
effectiveness of treatments.
(2) An overview of RCTs, with emphasis on this type of
research method as the 'gold standard' for evaluating the
effectiveness of health care treatments. The rationale
behind placebos, randomisation, and blinding was also
discussed.
(3) The currently known benefits and harms of HT for
postmenopausal women, based on results from observa-
tional studies and short-term RCTs, were discussed. The
statistical findings were reported, discussed and summa-
rised in lay terms.
(4) The rationale for a long-term RCT of HT was
explained.
Part 2: Explanation of WISDOM
(5) The background, purpose and procedures of the 15
year WISDOM trial was explained.
(6) The main inclusion and exclusion criteria of WIS-
DOM, allowing women to self screen themselves.
(7) The potential benefits for taking part in WISDOM
were discussed. This included individual benefits, such as
health follow-up and monitoring, to global benefits, such
as the contribution to knowledge about HT for future gen-
erations of women.
Part 3: Question time. This allowed general questions
from the audience to be answered in front of the other
women and accompanying partners, relatives or friends.
Personal questions could also be answered privately at the
end of the seminar.
At the end of the seminar, women were asked to complete
a brief questionnaire asking whether they were interested
in being telephoned by a WISDOM trial nurse to arrange
a screening visit. The questionnaire also included a check-
list of broad medical exclusions to confirm initial eligibil-
ity before screening.
Telephone calls
Those who attended the seminar, and were still interested
and eligible based on the post-seminar questionnaire,
were telephoned by a trial nurse within one week of the
seminar and invited to attend an initial screening inter-
view. Women who did not attend the seminar but who
gave a positive response of interest on their initial reply
slip were also telephoned by the research nurse. Since
these women had received only written information
about WISDOM, the nurse also explained to them the
main purpose and procedures of the trial, and confirmed
their interest and initial eligibility before inviting them to
screening.
Screening interview
The standardised screening interview for WISDOM is
described elsewhere [1]. Briefly, during the one-hour
standardised screening interview the trial nurse explained
the currently known harms and benefits of long-term HT,
the purpose and procedures of WISDOM, and conducted
an extensive eligibility check. If the woman was eligible
and willing to participate, informed written consent was
sought from the woman and her GP, and an appointment
was arranged 2 weeks later with the trial nurse to initiate
the 12 week 'run-in' phase prior to randomisation. Details
of those randomised and the outcomes of WISDOM are
described elsewhere [4].
The number of seminar attendees and non-attendees who
completed a screening visit, run-in and randomisation
visit was recorded, and a Chi-square test was performed
using SPSS 13.0 statistical software to test for differences
in recruitment rates between the two groups.
Feedback questionnaires
In November 2002 (5 weeks after stopping WISDOM),
anonymous feedback questionnaires were posted to all
840 women who had completed at least a screening visit
for the Adelaide WISDOM recruitment centre [5]. Women
were asked whether or not they had attended an initial
seminar for WISDOM, and asked to rate on a Likert scale
how helpful the seminar, one-to-one visit with the nurse
(screening interview) and information sheet were in their
decision to participate in WISDOM.
Results
Recruitment of women who attended the seminar
Figure 1 illustrates the Adelaide recruitment procedure for
WISDOM and the number of seminar attendees and non-
attendees who reached the screening, run-in and ran-
domisation phases of the trial. The mean number of
invited women attending seminars ranged from 12 – 81
per session (mean 44). This was limited by the size of the
practice, and its number of female patients aged 50–69
who received the initial invitation letter. Of the 1246Trials 2008, 9:5 http://www.trialsjournal.com/content/9/1/5
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Flowchart of Adelaide recruitment procedure Figure 1
Flowchart of Adelaide recruitment procedure.
Screening visits completed 
with attendees as of  
9
th July 2002: 492 (2.1%) 
39.5% of attendees
Screening visits completed 
with non-attendees as of 9
th
July 2002: 348 (1.5%) 
21.0% of non-attendees
Consent to enter Run-in 
phase as of 
9
th July 2002 :  
304 (1.3%) 
24.4% of attendees
Consent to enter Run-in 
phase as of 
9
th July 2002 :  
209 (0.9%) 
12.6% of non-attendees
Total invitation letters 
sent:  23,654
Postal Responses to 
invitation: 6,354 (26.9%)
No response: 
17,300 (73.1%)
Not interested : 2,101 (8.9%)
Self exclusion: 1,303 (5.5%)
Other reasons: 45 (0.2%)
Attended initial  
seminar: 
1,246 (5.3%)
Did not attend seminar but interested 
in being contacted:  
1,659 (7.0%)
Not interested / ineligible 
after seminar: 390 (1.6%)
31.3% of attendees
Interested and 
eligible: 794 (3.4%)
63.7% of attendees
Questionnaire  to ascertain 
interest and eligibililty 
Nurse telephone call 
Randomisations as of 
9
th July 2002 :  
167 (0.7%) 
13.4% of attendees
Randomisations as of 
9
th July 2002 :  
116 (0.5%) 
7.0% of non-attendees
Interested but not 
eligible: 62 (0.3%) 
5.0% of attendees
64 withdrawals 
124 waiting for Run-in 
74 withdrawals 
65 waiting for Run-In 
Nurse telephone call 
21 withdrawals 
116 still completing Run-in phase or 
waiting for Randomisation 
15 withdrawals 
78 still completing Run-in phase or 
waiting for Randomisation Trials 2008, 9:5 http://www.trialsjournal.com/content/9/1/5
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women who attended a seminar, 492 (39.5%) attended a
screening visit with a trial nurse, and 304 (24.4%) and
167 (13.4%) reached the run-in and randomisation
phases, respectively. In comparison, of the 1659 women
who did not attend a seminar, 348 (21.0%) attended a
screening visit, and 209 (12.6%) and 116 (7.0%) reached
the run-in and randomisation phases, respectively. Thus,
seminar attendees were nearly twice as likely to attend an
initial screening visit with a trial nurse (Chi square =
118.6, 1 df, p < 0.001) and go on to the run-in (Chi square
= 68.1, 1 df, p < 0.001) and randomisation (Chi square =
33.3, 1 df, p < 0.001) phases of the trial.
A higher proportion of non-attendees (74/348, 21.2%)
either withdrew or were not eligible after screening than
attendees (64/492, 13.0%)
Helpfulness of seminar
A total of 618/840 (73.6%) Adelaide participants
returned completed feedback questionnaires. A descrip-
tion of the respondents is provided elsewhere [5]. Three
hundred and seventy eight (61.2%) of the respondents
stated that they had attended an initial seminar prior to
enrolment in WISDOM. As shown in Table 1 below, of the
378 women who attended the seminar, 88.9% regarded
the seminar as either moderately helpful or very helpful in
their decision to participate in WISDOM. One-to-one
contact with the trial nurse and written information was
regarded as moderately or very helpful by 81.5% and
73.0%, respectively. For women who did not attend the
seminar (n = 235), one-to-one contact with the trial nurse
and written information was rated as moderately helpful
or very helpful by 78.3% and 73.7%, respectively.
Contact time spent with attendees and non-attendees
As shown in Figure 2, based on a sample of 100 seminar
attendees and 100 interested non-attendees, an estimated
average of 7.0 hours contact time was required to ran-
domise seminar attendees, compared to 8.2 hours contact
time for interested women who did not attend. Further,
the number of initial telephone calls required to confirm
interest or screen-out uninterested women was lower in
the attendee group (63 calls) than in the non-attendee
group (100 calls). Since duration of telephone calls was
not recorded, we have estimated each call to be 10 mins
duration in both groups. However, it is important to note
that the purpose of telephone calls to attendees was only
to arrange an appointment time for screening and not to
discuss the aims and procedures of WISDOM, or to con-
firm eligibility, so telephone calls to these women were
likely to be shorter.
Discussion
The results of this analysis suggests that running group
information seminars to facilitate the recruitment of
women for a large randomised placebo controlled trial
results in greater numbers screened and randomised,
fewer drop-outs, and less total recruitment time spent by
the research team. This technique was adopted when it
became apparent from the experience of the UK arm of
Table 1: Questionnaire responses to "What was most helpful in your decision to enter WISDOM?"
Attended seminar Did not attend seminar
N = 378 % N = 235 %
Reading the information that was sent to you
Not helpful 3 0.8 0 0
Somewhat helpful 55 14.6 22 9.4
Moderately helpful 142 37.6 77 32.8
Very helpful 134 35.4 96 40.9
Not applicable 18 4.8 8 3.4
Not specified 26 6.9 32 13.6
Attending the information evening
Not helpful 2 0.5
Somewhat helpful 11 2.9
Moderately helpful 77 20.4
Very helpful 259 68.5
Not applicable 13 3.4 155 66.0
Not specified 16 4.2 80 34.0
Seeing the trial nurse for the first time
Not helpful 9 2.4 5 2.1
Somewhat helpful 24 6.3 9 3.8
Moderately helpful 65 17.2 34 14.5
Very helpful 243 64.3 150 63.8
Not applicable 19 5.0 8 3.4
Not specified 18 4.8 29 12.3Trials 2008, 9:5 http://www.trialsjournal.com/content/9/1/5
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WISDOM that recruitment was slower than had been
anticipated from an initial pilot study.
Women who attended a group seminar conducted by our
research team were twice as likely to attend an initial
screening visit with a trial nurse and enrol to participate
than women who did not attend a seminar but only
received one-to-one interaction with the trial nurse. It
should be emphasised that this study was not a ran-
domised controlled trial to test seminars as an interven-
tion to improve recruitment, but rather, a cross sectional
study suggesting that seminars may be a worthwhile
recruitment strategy, which could be tested with a stronger
research methodology in future. At the very least, this
study implies that offering seminars is a good way of dif-
ferentiating those who will eventually participate in a trial
from those who do not.
We believe our recruitment procedure, where women
attended an information seminar and screened them-
selves for eligibility prior to attending a formal screening
session with a trial nurse, was more efficient than the pro-
cedures used to recruit patients in the UK. Following an
extensive notesearch of women patients aged 50–69 years
in general practices across the UK, 155,204 women were
invited to screening [4]. Although a high number of these
women (56,583) agreed to attend screening, only 16%
(8980) and 10% (5692) of those screened went on to par-
ticipate in the run-in and randomisation phases of the
trial, respectively [4]. In Adelaide, the notesearching step
was omitted in favour of women attending an informa-
tion seminar and screening themselves for eligibility, and
of the 840 women who attended screening, 61% and 34%
continued on to participate in the run-in and randomisa-
tion phases of the trial.
It is possible that the seminar increased women's motiva-
tion to participate. However, as women were not ran-
domly allocated to attend the seminar or receive only one-
to-one contact with the trial nurse, the higher participa-
tion rate observed amongst seminar attendees may simply
be due to selection bias. That is, attendees may have been
more motivated than non-attendees to participate in WIS-
DOM upon first receiving the invitation letter, and thus
chose to attend the seminar because they wanted to be as
informed as possible about the trial before enrolling. It
would have been useful to compare the age and sociode-
mographic characteristics of women in the attendee and
non-attendee groups but this information was not col-
lected on reply slips.
Conducting seminars with potential participants prior to
enrolment in an RCT may confer several advantages for
the participant, research team and general practice. For the
participant, a seminar conducted by the research investi-
gator provides expert, up-to-date information about the
research area and clinical trial, and a more comprehensive
discussion of the characteristics of RCTs, including clinical
equipoise, the need for randomisation to placebo or treat-
ment and the need for blinding to treatment. The seminar
also gives participants an opportunity to ask questions of
senior researchers and to meet and share these questions
and concerns with other potential participants, partners,
friends and relatives. This group setting may provide par-
ticipants with the time and space they need to independ-
ently consider all facets of the trial before making a
personal commitment to participate, and it could be per-
Estimated total contact time required for each group and  number of potential participants reaching randomisation  (based on 100 potential participants in each group) Figure 2
Estimated total contact time required for each group and 
number of potential participants reaching randomisation 
(based on 100 potential participants in each group).
100 Attendees 
Group seminars: 
5.5 hours (based on mean of 
44 attendees per 2 hr session, and 
including 1.5 hours set-up, 
administration and travelling time)
63.7 Telephone calls 
(10 mins each): 
10.6 hours 
39.5 Screening visits 
(1 hour each): 
39.5 hours 
24.4 Run-in visits 
(1 hour each): 
24.4 hours 
13.4 Randomisation 
visits (1 hour each): 
13.4 hours 
93.4 hours for 
13.4 randomised/ 
100 attendees 
100 “Interested” Non-
Attendees 
Group seminars: 
0 hours
100 Telephone calls 
(10 mins each): 
16.7 hours 
21 Screening visits 
(1 hour each):  
21.0 hours
12.6 Run-in visits 
(1 hour each):  
12.6 hours
7.0 Randomisation 
visits (1 hour each):  
7.0 hours
57.3 hours for 
7.0 randomised/ 
100 non-attendees
7.0 hours per 
randomised patient
8.2 hours per 
randomised patientTrials 2008, 9:5 http://www.trialsjournal.com/content/9/1/5
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ceived as less intimidating than individual meetings with
their GP or trial nurse. The group seminar also confers
benefits for the research team. Potential participants,
regardless of whether they attended the seminar or not,
were telephoned by the trial nurse to discuss participation
and invited to a screening visit. However, seminar attend-
ees who recognised that they were ineligible or not inter-
ested in participating at the end of the seminar had the
opportunity to inform the research team via the post-sem-
inar questionnaire, and so these women did not need to
be telephoned. Further, the telephone calls to attendees
were probably shorter, since there was no need to spend
time explaining the purpose, procedures or eligibility cri-
teria of the trial. In addition, seminar attendees were less
inclined to drop-out after their screening visit than non-
attendees.
Although numerous studies have evaluated the effective-
ness of various recruitment strategies, to our knowledge
few have focused on the effectiveness of group seminars
for increasing recruitment. One research team found
group information sessions to be a more efficient and cost
effective recruitment strategy than individual sessions
when recruiting female university students for a commu-
nity-based trial of chlamydia screening to prevent pelvic
inflammatory disease [6]. Another team found group
meetings with families to be a useful strategy for recruiting
children to RCTs, where parents must provide consent [7].
In contrast, an educational intervention that included
group seminars was not more effective than written infor-
mation for increasing recruitment of older cancer patients
to treatment trials [8]. These studies suggest that, if semi-
nars are indeed useful, their effectiveness may vary in dif-
ferent populations.
Our recruitment process enables research teams to take
the responsibility and effort of recruitment away from
busy GPs and practice staff. There was no need for GPs or
practice nurses to screen their patient records to identify
potentially eligible patients, since all women within the
eligible age range (50–69 years) were sent detailed trial
information, and asked to screen themselves for initial eli-
gibility at the invitation letter stage, at the seminar (via
post-seminar questionnaire) or during their telephone
call with the trial nurse. Secondly, there was no need for
GPs or practice nurses to recruit participants since all sem-
inars were conducted by the research team (BJP, NPS and
AHM), and telephone calls and screening interviews (as
well as all subsequent trial visits) were conducted by ded-
icated trial nurses. GPs were only required to assist the
trial nurses after enrolment, when monitoring participant
health outcomes and reporting adverse events was
required.
The proportion of respondents to our initial invitation let-
ter was considerably low, at 27%. However, this is perhaps
not surprising given that we asked women to screen them-
selves for eligibility using an extensive list of inclusion
and exclusion criteria provided in the information sheet.
One of the exclusions was current use of HT for women
with a uterus and a range of health conditions including
breast cancer, any other cancer in the last ten years,
endometriosis, venous thromboembolism, gall bladder
disease, heart disease and stroke. According to a 2002
South Australian Health Omnibus survey, 28% of women
aged over 50 were currently using HT in 2000, with ever-
use of HT at 43% [9]. Thus, many women who were sent
our invitation letter would have been using HT or had
experienced one of the health exclusion criteria, so
believed themselves to be ineligible and may have disre-
garded the letter without responding. Many other women
who had taken HT previously may have experienced side
effects and so may not have been willing to enter a trial
where they may required to take HT again.
Conclusion
Group seminars conducted by the research team may be a
useful strategy for maximising participant recruitment to
RCTs, particularly in the busy general practice setting.
Seminars may increase a participant's understanding of
the research topic and the principles of RCTs, allowing
them to make a more informed choice about participation
and their eligibility. They allow potential trial participants
to meet the principal investigators, other potential partic-
ipants and hear each other's views in a relaxed setting. It is
possible that motivation to join a long-term study, and
any altruistic feelings for helping medical research, is
enhanced by hearing directly from senior investigators
and by hearing the questions and reactions of other
women in the audience. Providing information about the
trial's background, purpose and procedures to a group
rather than individually, and allowing participants to
screen themselves for eligibility, may significantly reduce
the amount of time spent by research or practice staff
recruiting participants. Nevertheless, given the cross-sec-
tional nature of our study, the potential for selection bias
was a possibility, and thus future randomised controlled
trials to test seminars as an intervention to improve
recruitment are needed.
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